

Scientific Panel on Dietetic Products, Nutrition and Allergies

Agenda of the 78th Plenary Meeting

4-6 April 2017, Parma (Italy)

Auditorium:

Meeting open to Observers

OPEN SESSION

5-6 April 2017

5 April 2017, 9:00-18:00

6 April 2017, 9:00-13:30

- 1. Welcome and apologies for absence - [*5 April am*]**
- 2. Brief introduction of Panel members and observers [*5 April am*]**
- 3. Adoption of the agenda**
- 4. Declarations of Interest of Scientific Panel Members**
- 5. Presentation of the Guidelines for Observers [*5 April am*]**
- 6. Report on written procedures since 77th Plenary meeting [*5 April am*]**
- 7. Scientific outputs submitted for possible adoption/endorsement for release for public consultation**
 - 7.1. Draft technical report on the outcome of the public consultation on the draft scientific opinion on the safety and suitability for use by infants of a follow-on formulae with a protein content of at least 1.6 g/100 kcal (EFSA-Q-2016-00860) - [*5 April am*]
 - 7.2. Nestlé Nutrition – Scientific Opinion on the safety and suitability for use by infants of a follow-on formula with a protein content of at least 1.6 g/100 kcal (EFSA-Q-2016-00275) - [*5 April am*]
 - 7.3. Draft technical report on the outcome of the public consultation on the draft scientific and technical guidance for the

preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates (EFSA-Q-2016-00300) - [\[5 April am\]](#)

7.4. Draft scientific and technical guidance for the preparation and presentation of an application for authorisation of an infant and/or follow-on formula manufactured from protein hydrolysates (EFSA-Q-2016-00276) - [\[5 April am\]](#)

7.5. Draft technical report on the outcome of public consultation on Dietary Reference Values for Vitamin K (EFSA-Q-2015-00669) - [\[5 April pm\]](#)

7.6. Draft opinion on Dietary Reference Values for vitamin K (EFSA-Q-2011-01232) - [\[5 April pm\]](#)

7.7. Draft opinion on Dietary Reference Values for riboflavin (EFSA-Q-2011-01222) - [\[5 April pm\]](#)

8. New Mandates [\[6 April am\]](#)

9. Feedback from the Scientific Committee/Scientific Panels, EFSA, the European Commission [\[6 April am\]](#)

9.1. Scientific Committee

9.2. EFSA including its Working Groups /Task Forces

9.3. European Commission

10. Other scientific topics for information and/or discussion

10.1. ANS Panel's draft guidance for the safety evaluation of sources of nutrients (EFSA-Q-2016-00150) - [\[6 April 9-10 am\]](#)

10.2. Testing applicability of the Guidance on uncertainty in EFSA scientific assessment (EFSA-Q-2013-00738) - [\[5 April pm\]](#)

11. Questions from and answers to Observers (in application of the guidelines for Observers) - [\[6 April 11-13 am\]](#)

12. Any other business - [\[6 April am\]](#)

CLOSED SESSION
4 April 2016, 9.00-18.00

Items for Closed Session owing to confidential business information/proprietary data

13. Scientific outputs submitted for possible adoption

***Applications pursuant to Article 14/13.5 of Regulation (EC)
No 1924/2006 [4 April am]***

- 13.1. Marks and Spencer – “Product formulated with a carbohydrate: protein ratio < 1.8. For adults with excess body weight, this helps to achieve a reduction in body weight and body fat when consumed as part of an energy restricted diet” (Art 13.5, 0449_UK, EFSA-Q-2016-00436)
- 13.2. Suomen Terveystuote Oy – “Curcumin and normal functioning of joints” (Art 13.5, 0451_FI, EFSA-Q-2016-00856)
- 13.3. Laboratoire Nurilia – “Condensyl®” and “decreases sperm DNA damage (sperm nuclear decondensation index and DNA fragmentation index). High sperm DNA damage (sperm nuclear decondensation index and DNA fragmentation index) is a risk factor for male subfertility/infertility” (Art 14, 0450_FR, EFSA-Q-2016-00665)

Novel Foods [4 April pm]

- 13.4. InovoBiologic, Inc. – Draft opinion on Alginate-Konjac-Polysaccharide complex (EFSA-Q-2015-00469)
- 13.5. Ocean Spray Cranberries, Inc. - Draft opinion on cranberry extract (EFSA-Q-2016-00325)
- 13.6. Naturalendo Tech Co., Ltd - Draft statement on additional data on Estrog-100TM (EFSA-Q-2017-00040)